{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-24-000233","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.783183+00:00","generated_at":"2026-06-04T22:04:37.185173+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline","bullets":["Terry Lierman appointed as independent Class B director, effective March 12, 2024.","Lierman brings healthcare leadership: co-chair IHV, founder of Children's Research Institute, PanCAN, NOFAS.","Granted options to buy 150,000 shares at $0.30/share; 50,000 vest immediately, balance over 2025-2026.","His expertise will support Phase 2 trial of IGC-AD1 for agitation in Alzheimer's and preclinical TGR-63.","CEO Ram Mukunda cites Lierman's strategic guidance as pivotal for pipeline advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-24-000233","json":"https://secwatch.observer/filing/0001185185-24-000233.json","markdown":"https://secwatch.observer/filing/0001185185-24-000233.md","text":"https://secwatch.observer/filing/0001185185-24-000233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/0001185185-24-000233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/igcpharma20240311_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:04:37.185173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b9a6ba0d8","claim":"Terry Lierman was appointed as independent Class B director at IGC Pharma, Inc..","evidence_excerpt":"On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000233/0001185185-24-000233-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"independent Class B director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}